Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29084532 | 0.72 | BUB1 (0.37) | — | |
| SCHEMBL23647904 | 0.72 | HTR2A (0.33) | LPLLIPG | |
| SCHEMBL19785576 | 0.71 | EGFR (0.33) | LPLLIPG | |
| SCHEMBL994278 | 0.70 | — | — | |
| SCHEMBL632830 | 0.68 | — | — | |
| SCHEMBL632831 | 0.66 | EGFR (0.31) | LPLLIPG | |
| SCHEMBL16535122 | 0.65 | — | — | |
| SCHEMBL27229415 | 0.65 | EGFR (0.34) | LPLLIPG | |
| SCHEMBL29763539 | 0.64 | LPL (0.33) | LPLLIPG | |
| SCHEMBL23104615 | 0.64 | LPL (0.33) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132447-A1 | POLYNUCLEOTIDE LIBRARIES HAVING CONTROLLED STOICHIOMETRY AND SYNTHESIS THEREOF | Twist Bioscience Corporation (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260117422-A1 | METHODS AND COMPOSITIONS FOR GENOMIC ANALYSIS | Twist Bioscience Corporation (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4698320-A1 | PARALLEL SUBSTRATES FOR MULTIPLEXING BIOMOLECULE PROCESSING | Twist Bioscience Corporation (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12522868-B2 | Polynucleotides, reagents, and methods for nucleic acid hybridization | Twist Bioscience Corporation (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250352972-A1 | HIGHLY ACCURATE DE NOVO POLYNUCLEOTIDE SYNTHESIS | Twist Bioscience Corporation (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4594531-A1 | METHODS AND COMPOSITIONS FOR GENOMIC ANALYSIS | Twist Bioscience Corporation (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12357959-B2 | Highly accurate de novo polynucleotide synthesis | Twist Bioscience Corporation (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250188445-A1 | LIBRARIES FOR NEXT GENERATION SEQUENCING | Twist Bioscience Corporation (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4504964-A2 | LIBRARIES FOR METHYLATION ANALYSIS | Twist Bioscience Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024220478-A1 | PARALLEL SUBSTRATES FOR MULTIPLEXING BIOMOLECULE PROCESSING | Twist Bioscience Corporation (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| EP-2444084-A1 | Use of PI3K inibitors for the treatment of obesity | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| EP-2419429-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-22 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| WO-2011101429-A1 | PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | LPL 2508/4885LIPG 2463/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | LPL 2570/4885LIPG 1579/4885 |
| US-20260132447-A1 | POLYNUCLEOTIDE LIBRARIES HAVING CONTROLLED STOICHIOMETRY AND SYNTHESIS THEREOF | UPF1, POLM, POLRMT | LPL 3095/4885LIPG 4111/4885 |
| US-20260117422-A1 | METHODS AND COMPOSITIONS FOR GENOMIC ANALYSIS | DNMT3A, BRCA1, DNMT1 | LPL 1081/4885LIPG 4030/4885 |
| US-12357959-B2 | Highly accurate de novo polynucleotide synthesis | POLM, POLRMT, POLN | LPL 2806/4885LIPG 3196/4885 |
| US-20250352972-A1 | HIGHLY ACCURATE DE NOVO POLYNUCLEOTIDE SYNTHESIS | POLM, POLRMT, POLN | LPL 2806/4885LIPG 3196/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | LPL 2600/4885LIPG 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.